Page 1,558«..1020..1,5571,5581,5591,560..1,5701,580..»

First Indy 500 Driver with Diabetes Talks About Racing, Life with His … – Healthline

Posted: May 27, 2017 at 3:40 pm

It all started with a skin rash.

Ten years ago, race car driver Charlie Kimball went to his doctor to check out that small rash on his arm.

In the course of their conversation, the physician learned that Kimball had also been unusually thirsty in recent days.

When he weighed Kimball, the doctor discovered his patient had lost 25 pounds in five days.

He immediately suggested Kimball be tested for diabetes.

Kimball admits he was pretty clueless about the disease. He even asked his doctor if he could prescribe antibiotics for it.

I didnt know what it was or what it involved, Kimball told Healthline.

He soon found out when he was officially diagnosed at age 22 with type 1 diabetes.

Since that time, Kimball has become educated about diabetes.

He has also adjusted his life, both at home and behind the wheel of his race car.

A few years after his diagnosis, Kimball became the first person with diabetes to be allowed to drive in the Indianapolis 500.

On Sunday, he will compete in his seventh Indy 500 race.

As he circles that famed track the required 200 laps, Kimball will have a water bottle and a container of orange juice by his side.

Hell also be watching his blood glucose level on his dashboard.

Read more: Athletes with diabetes to follow on social media

Kimball concedes his diabetes diagnosis was a bit of a shock.

At age 22 you feel 10 feet tall and bulletproof, he said.

Kimball immediately had to start changing his daily routine.

He now takes insulin four times per day. One dose is a long-lasting insulin he takes in the morning. The other three are fast-acting insulin he takes after each meal.

Kimball also watches his diet much more closely.

He has learned that the carbohydrates in pizza, for example, take longer to enter the blood stream than most foods. He learned that corn has carbohydrates, too.

Kimball was initially worried about whether hed be able to continue race car driving.

I was concerned about getting back in my race car, he recalled. The race car is the only place I feel really alive.

That involved more than just driving.

Race car drivers are athletes.

They are handling vehicles without power steering that are traveling around 200 miles an hour.

The stress keeps their heart rate high throughout an entire three-hour race. They can lose seven pounds of water weight due to the heat of the car. And they can burn more than 1,100 calories in a single race.

Im always concerned about the safety element and the performance element, he said.

Kimball quickly learned, however, that his new dietary routine was actually enhancing his skills.

It helps me be a better athlete, he commented.

During his races, Kimball wears special sensors on his skin that monitor his body functions.

On his dashboard, he can monitor his blood glucose level and other health-related data along with his cars speed and how many laps he has completed.

Kimball said it isnt a coincidence hes the first Indy 500 driver with diabetes.

Until recent years, there wasnt the technology to provide enough support and assistance to a driver with this particular condition.

In addition, Kimball said, most people with type 1 diabetes are diagnosed when they are children.

At that stage, most kids with the disease dont envision becoming a race car driver.

Kimball, on the other hand, was already doing it.

I wasnt going to let diabetes get in the way of my lifes dream, he said.

Read more: NASCAR driver getting the word out on colorectal cancer

Kimball hopes his drive to continue his race car career will inspire children and others with diabetes.

He said he wants youngsters to feel like they still can do whatever they want, whether its being an athlete, a rock climber, or a chief executive officer.

I want them to be able to chase their dreams, he said.

Kimball is also participating in a program at Michigan State University to study exercise physiology and race car driving.

David Ferguson, PhD, an assistant professor of kinesiology, oversees the program. Ferguson has been doing this kind of research for 12 years.

When Kimball came along, Ferguson saw an opportunity to hone his research even more.

Charlie is a good model for us to work with, Ferguson told Healthline.

One of the more interesting experiments the researchers have worked on is how driving on an oval track seemed to be a more difficult task for Kimball than driving on a more winding, surface street race course.

To discover what was happening, the researchers outfitted Kimball with a clear plastic box that encased his body from the waist down. The case was accompanied by some wooden blocks, cushions, and a bicycle seat.

By taking readings with the box, the researchers discovered that the blood in Kimballs lower legs was pooling more on oval courses because there are stronger g-forces.

With that knowledge, they set up a training schedule that exposed Kimball to that type of g-force to help him condition himself for it.

Ferguson said they hope to use what they learn from their experiments with Kimball to help the general population with diabetes management.

For Kimball, all of this helps him when hes on the race track.

The past two years, he has finished third and fifth in the Indy 500.

Hes hoping for an even better finish on Sunday.

If you want to keep track, Kimball will be in the car with the number 83 and the Novo Nordisk sponsor decals.

Read more: World Cup soccer stars next goal is to conquer lupus

Excerpt from:
First Indy 500 Driver with Diabetes Talks About Racing, Life with His ... - Healthline

Posted in Diabetes | Comments Off on First Indy 500 Driver with Diabetes Talks About Racing, Life with His … – Healthline

Good Samaritan’s Welch Diabetes Education Center Recognized by The American Diabetes Association – Washington Times Herald

Posted: May 27, 2017 at 3:40 pm

The Diabetes Self-Management Education (DSME) program through the Welch Diabetes Education Center at Good Samaritan has been awarded continued recognition from the American Diabetes Association (ADA). The program at Good Samaritan was originally recognized in August of 1994 and offers high-quality education services to the patients it serves.

The ADA Education Recognition effort, begun in the fall of 1986, is a voluntary process which assures that approved education programs have met the National Standards for Diabetes Self-Management Education Programs. Programs that achieve Recognition status have a staff of knowledgeable health professionals who can provide state-of-the-art information about diabetes management for participants.

Self-management education is an essential component of diabetes treatment. One consequence of compliance with the National Standards is the greater consistency in the quality and quantity of education offered to people with diabetes. The participant in an ADA Recognized program will be taught, as needed, self-care skills that will promote better management of his or her diabetes treatment regimen.

The Welch Diabetes Education Center believes that education is the key to empowering the person with diabetes to better manage his or her disease, said Stacy Hinkle, RN, BSN, CDE, Diabetes Program Coordinator. Educating our patients on how they can avoid the complications of diabetes and achieve an optimum health status is our ultimate goal.

All approved education programs cover the following topics as needed: diabetes disease process; nutritional management; physical activity; medications; monitoring; preventing, detecting, and treating acute complications; preventing, detecting, and treating chronic complications through risk reduction; goal setting and problem solving; psychological adjustment; preconception care, management during pregnancy, and gestational management.

Assuring high-quality education for patient self-care is one of the primary goals of the Education Recognition program. Through the support of the health care team and increased knowledge and awareness of diabetes, the patient can assume a major part of the responsibility for his/her diabetes management. Unnecessary hospital admissions and some of the acute and chronic complications of diabetes may be prevented through self-management education.

Read this article:
Good Samaritan's Welch Diabetes Education Center Recognized by The American Diabetes Association - Washington Times Herald

Posted in Diabetes | Comments Off on Good Samaritan’s Welch Diabetes Education Center Recognized by The American Diabetes Association – Washington Times Herald

Study: Too Little Sleep Doubles Mortality in Those With Heart, Diabetes Risks – Voice of America

Posted: May 27, 2017 at 3:40 pm

People with a common cluster of symptoms that puts them at increased risk of heart disease and diabetes are two times as likely to die as people without those risk factors if they get less than six hours of sleep per night.

That was the finding of a new study conducted by researchers at Pennsylvania State College of Medicine and reported in the Journal of the American Heart Association.

So-called metabolic syndrome is marked by elevated blood sugar, high blood pressure and cholesterol, and excess fat around the waistline. A diagnosis of metabolic syndrome also includes a high body mass index (BMI), a measurement of a person's weight relative to his height.

People with a high BMI and other symptoms of metabolic syndrome are at increased risk of developing heart disease and diabetes.

Study participants

In the study, a group of 1,344 adults agreed to spend one night in a sleep clinic. Almost 40 percent of the participants were found to have at least three of the risk factors of metabolic syndrome.

When the participants were followed up an average of 16 years later, 22 percent of them had died.

Compared with those without metabolic syndrome, investigators found those with a cluster of heart disease and diabetes risk factors were 2.1 times more likely to have died of stroke if they slept less than six hours during their night in the lab.

If they had slept more than six hours, those with metabolic syndrome were about 1 times more likely to have suffered a fatal stroke than normal participants.

Finally, those with metabolic syndrome who slept less than six hours were almost two times more likely to have died of any cause compared with those without the heart disease and diabetes risk factors.

The study is the first to examine the impact of sleep duration on the risk of death in patients with metabolic syndrome.

More trials planned

If you have metabolic syndrome, the study's authors note it is important to notify your doctor if you are not getting enough sleep to reduce the risk of death from heart attack or stroke.

The researchers plan future clinical trials to determine whether increasing the length of quality sleep, in addition to lowering blood pressure and glucose, improves the prognosis for people with metabolic syndrome.

The American Heart Association recently issued a scientific statement noting that an increasing number of Americans suffer from sleep difficulties, either involuntarily or because they'd rather stay up late, and this trend may be associated with increased cardiovascular risks and outcomes.

Read the original post:
Study: Too Little Sleep Doubles Mortality in Those With Heart, Diabetes Risks - Voice of America

Posted in Diabetes | Comments Off on Study: Too Little Sleep Doubles Mortality in Those With Heart, Diabetes Risks – Voice of America

Students, Young Adults With Diabetes National Conference This Weekend in Orlando – West Orlando News

Posted: May 27, 2017 at 3:40 pm

Young people from across the country are gathering over Memorial Day weekend to learn, laugh, and create connections focused on their shared health condition type 1 diabetes (T1D). The conference will be led by organizational founder and inspirational T1D leader, Nicole Johnson, and also features T1D musician and American Idol semi-finalist Adam Lasher, and T1D American Ninja Warrior Kyle Cochran. The conference of over 125 young people is being hosted by Dr. Nicole Johnson, a former Miss America with diabetes residing in Florida.

Here are the details of the conference: WHO: College Students & Young Adults Affected by Type 1 Diabetes WHAT: Students/Young Adults With Diabetes National Conference WHEN: Saturday, May 27 & Sunday, May 28 WHERE: Sea World Renaissance Hotel, 6677 Sea Harbor Drive, Orlando FL

Students/Young Adults With Diabetes aims to create a community for young adults with diabetes ages 18-30 on both college campuses and in local communities across the country. This non-profit organization equips young adults with the tools and information they need to succeed, and provides professional and social opportunities to create peer networks.

Not only will conference attendees enjoy fun activities including the SWD Amazing Race, they will discuss topics involving alcohol and diabetes, health insurance and finances, diabetes advocacy, eating disorders and depression, and advances in research including the artificial pancreas and other new technology tools.

The genesis of this organization began with the type 1 diagnosis of a college student at the University of South Florida in 1993. That college student, Nicole Johnson, was told to drop out of school, give up on her career dreams and live a predictable life. Ignoring this advice, Johnson pursued her dreams and became one of the countrys greatest role models as Miss America 1999. Johnson has devoted her life to improving health outcomes for those living with diabetes while earning three advanced degrees including a doctorate in public health.

For more information about Students/Young Adults With Diabetes: http://www.studentswithdiabetes.com

Read more:
Students, Young Adults With Diabetes National Conference This Weekend in Orlando - West Orlando News

Posted in Diabetes | Comments Off on Students, Young Adults With Diabetes National Conference This Weekend in Orlando – West Orlando News

Scientists wary as Texas mulls allowing sale of unproven drugs – Texas Tribune

Posted: May 26, 2017 at 8:45 am

A group of scientists and medical professionals is sounding the alarm in the final days of the Texas legislative session about a little-noticed bill that would allow manufacturers of unproven drugs to sell their products to dying patients.

Supporters of House Bill 3236 by state Rep. Kyle Kacal, R-College Station, say it could help incentivize drugmakers to get promising, experimental drugs onto the market and into needy patients hands. Its detractors say it would allow drug companies and quack doctors to use fake medicine to take advantage of sick, vulnerable families.

After emotional pleas from state lawmakers invoking family members with terminal illness, the Texas House passed the measure earlier this month in a unanimous 142-0 vote, just minutes before a critical deadline. The bill is now waiting to be heard by the Senate State Affairs Committee.

From the House floor, Kacal whose mother died of ovarian cancer said he hoped it would help make experimental drugs "accessible to everybody."

The Texas Tribune thanks its sponsors. Become one.

Asked by state Rep. Jonathan Stickland, R-Bedford, about concerns that the proposal could have unintended consequences, Kacal said he had "vetted the bill very well."

But that has not eased the fear of some patient advocates.

Its the dirtiest, most corrupt, most transparently fraudulent bill Ive ever seen in my life, said Will Decker, a Houstonimmunologist who sits on the medical board for the advocacy group Texans for Cures. It exists for one purpose and one purpose only: to let patients pay for snake oil.

The debate this year is a new development in Texas right to try movement, which advocatesthat terminally ill patients should be allowed to try long-shot therapies that havent received final approval by the U.S. Food and Drug Administration a process that can be lengthy.

The movement, backed by the libertarian Goldwater Institute, is gaining traction in state legislatures around the country; 35 other states havepassed similar laws. Of those, Texas is the only statethat prohibits patients from paying for experimental drugs, said Starlee Coleman, a policy adviser for the Arizona-based institute.

In an interview, Kacalsaid his bill was meant to reduce barriers for sick patients to access potentially life-saving drugs. While most drugs provided through compassionate use are donated to patients, free of charge, by large pharmaceutical companies, Kacal said smaller drug-makers need to be able to recoup some costs by charging patients.

The Texas Tribune thanks its sponsors. Become one.

If [smaller drug companies] say yes, but I need a small, nominal fee, I dont think the patient or the doctor is going to argue, he said. Were going to find a way to get that product to the individual.

The FDA already has a compassionate use program to helpterminally ill peopleaccess unapproved drugs. But few patients take advantage of the program; in 2015, about 1,900 patients applied for drugs through the program, according to STAT News.

Texas right to try law, passed in 2015, applies to drugs that have passed the FDAs phase 1 clinical trial, which essentially verifies that the drug will not harm a patient but doesn'tprove a drugs effectiveness.

The 2015 law requirespharmaceutical companies to provide experimental drugs without compensation, butKacals bill would allowdrugmakers tocharge patients for the costs of, or the costs associated with, the manufacture of the investigational drug.

Federal regulations prohibit companies fromprofiting fromexperimental medicine. Michelle Wittenburg,a lobbyist and president of theKK125 Ovarian Cancer Research Foundationwho supports Kacals bill,said thereare simply not enough patients receiving drugs through the federal compassionate use program to tempt bad actors who might want to take advantage of desperate people.

Youd have to have a lot of people seeking and getting it for anyone even someone trying to be a bad actor to actually make money off of it, she said.

The measure is backed by industry players including CellTex Therapeutics, a stem cell research company known in Texas political circles because former Gov. Rick Perry used to serve on its board (the company was involved in a back surgery Perry underwent in 2011 in which he received anexperimental injection of his own stem cells, a therapy that isnt FDA approved). In 2013, after a warning from the FDA, the companymoved its treatment operations to Mexico.

Sally Temple, the president of the International Society for Stem Cell Research, wrote Texas lawmakers this month to oppose the bill, saying it would allow companies to sell unsafe and ineffective therapies.

The Texas Tribune thanks its sponsors. Become one.

It may sound like an appealing idea to allow seriously ill patients accelerated access to experimental therapies, she wrote. However, in the absence of full clinical testing, these bills will allow snake oil salesmen to sell unproven and scientifically dubious therapies to desperate patients.

Disclosure: CellTex Therapeutics has been a financial supporter of The Texas Tribune. A complete list of Tribune donors and sponsors is availablehere.

Original post:
Scientists wary as Texas mulls allowing sale of unproven drugs - Texas Tribune

Posted in Arizona Stem Cells | Comments Off on Scientists wary as Texas mulls allowing sale of unproven drugs – Texas Tribune

Lakeland Community College biotechnology sciences students getting boost from grant – News-Herald.com

Posted: May 26, 2017 at 8:43 am

Thanks to a $40,320 grant from the Ohio Department of Higher Education, some hard-working Lakeland Community College biotechnology students will be eligible for scholarships to cover their tuition and fees.

The program is called Choose Ohio First and is aimed at helping students pursuing degrees in science, technology, engineering, mathematics and medicine or STEMM, its associated web page shows.

In Lakelands case, the grant applies to biotechnology science students who meet certain criteria, a media release from the school confirms.

Students who receive this scholarship will have their tuition fully covered at Lakeland, said Joe Deak, chairman of the schools biotechnology science program.

Advertisement

He added that two Lakeland Community College students are now using this funding.

The scholarship covers up to $4,000 in tuition and fees for biotechnology students who dont receive PELL grants, according to Lakelands release.

It goes on to explain that high school graduates who passed chemistry with a C or better are encouraged to apply if they fit the following criteria:

Have an interest in a career in the laboratory biological sciences or data/analysis management as it pertains to biological data

Have a 3.0 overall GPA

Place into college algebra

Reside in Ohio.

Lakelands recent investments in its science and health technology programs and facilities have been making headlines in recent years, especially with the 2015 passage of its capital improvement bond issue, which is being used to fund a $40 million renovation and expansion of the colleges 20-year-old Health Technologies Building, bring the science hallway renovation to completion and help with other infrastructure improvements.

This is the stuff of the future, confirmed Arts & Sciences Division Dean Steven Oluic, who was on hand at a Sept. 1 open house for the renovated, third-floor science wing, when students, teachers, staff and anyone interested could see it, tour the classrooms and labs and learn about all the new, cutting-edge technology there.

I will submit to you that our biology, chemistry and physical science labs are among the best in the area, Oluic said. Really, youd be hard-pressed to find better labs.

College President Morris W. Beverage agreed.

When I went to Lakeland in 1972 and 1973, in the original labs up there, they were new, he said. This is the sort of thing you do every 40 or 50 years and you do it right. And, to do it right, you make sure the equipment and technology the students will be using are the standard of what theyll be using when they leave here. We want our students to experience what theyre going to experience in the world when they move on from here.

For Deak, theres no question thats exactly what Lakelands students are getting.

Deak said that, in his 20 years with the schools program, hes always been able to find grant money to keep it at the cutting edge and, thanks to this latest round of funding, the department is able to offer an unprecedented level of training to students who will likely go on to hit the ground running in roles which may not even exist yet.

Our folks wind up in research and development, quality control and medical lab technology, he said, just naming a few, and he added that the lab in which he answered these questions would pretty much be the envy of anyone at Case Western Reserve or Cleveland State University.

There are numbers to prove it, too.

According to Lakelands statement about the Choose Ohio First grant, Lakelands biotechnology science program has more than a 95 percent placement rate into jobs or transfer to a four-year school.

Institutions where graduates matriculate include Case Western Reserve University, Cleveland State University, Indiana Wesleyan University, John Carroll University, Lake Erie College and Youngstown State University, the statement reads. Lakeland also has a 2+2 articulation with Ursuline College, which allows students to transfer all of their credits and graduate with a bachelors degree in two additional years or less.

Deak said some students are even fortunate enough to land jobs with employers who actually pay their tuition for them.

After graduating from Lakeland, many students are then able to receive tuition waivers or reimbursements from their employers to reduce, or eliminate, the cost of the bachelors degree, he said.

More:
Lakeland Community College biotechnology sciences students getting boost from grant - News-Herald.com

Posted in Biotechnology | Comments Off on Lakeland Community College biotechnology sciences students getting boost from grant – News-Herald.com

Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review – Investorplace.com

Posted: May 26, 2017 at 8:43 am

By Robert Martin, InvestorPlace Writer|May 22, 2017, 11:12 am EDT

Puma Biotechnology Inc (NASDAQ:PBYI) jolted as much as 80% higher on Monday morning on news that theU.S. Food & Drug Administration posted a seemingly positive review of Pumas breast cancer drug, neratinib, ahead of an official vote Wednesday. PBYI then settled back to just 60% gains a few hours into the trading day.

The FDA asked a few questions and raised a few concerns, notably, tolerability of neratinib in this patient population is a concern given the frequent dose interruptions, reductions, and discontinuations observed, mostly due to diarrhea.

Specifically, 95% of patients in clinical trials suffered from diarrhea, with 40% of those suffering the grade 3 form of the side effect.

However, on the whole, PBYI investors seemed pleased with what the FDA did (and didnt) ask, taking the review as an encouraging sign ahead of the companys Oncologic Drugs Advisory Committee meeting, scheduled for Wednesday.

Neratinib (PB272) is being tested for the extended adjuvant treatment of HER2-positive early stage breast cancer. The drug is meant for patients who have already received Herceptin.

The FDA preview said that the primary analysis showed an improvement with neratinib, and that despite changes made to the clinical trial, the results of sensitivity analyses appear to be generally similar to the primary analysis results, supporting an effect of neratinib.

The results are receiving a warm welcome from PBYI stock longs, who have suffered a roughly 80% decline from 2014 highs even after todays boffo gains.

The company has been a hotbed of volatility thanks to its dependence on this single candidate Puma Biotechnology is pre-revenue, and has been incurring increasingly larger net losses over the past few years. Specifically, red ink of about $55 million in 2013 has ballooned to losses of $276 million last year.

As of this writing, Robert Martin did not hold a position in any of the aforementioned securities.

Article printed from InvestorPlace Media, http://investorplace.com/2017/05/puma-biotechnology-inc-pbyi-pops-60-fda-review/.

2017 InvestorPlace Media, LLC

More:
Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review - Investorplace.com

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review – Investorplace.com

Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today – Madison.com

Posted: May 26, 2017 at 8:43 am

Wednesday was a good day for stocks, and the Dow Jones Industrials and S&P 500 both climbed through milestone levels. Most market participants attributed the positive sentiment to the Federal Reserve, which released the minutes of its latest monetary policy meeting during the afternoon. The central bank revealed plans to clamp down on the size of its balance sheet, which it initially expanded in the aftermath of the financial crisis to provide liquidity to the bond market and additional stimulus to the U.S. economy. Investors were pleased that the Fed believes that it's no longer necessary to extend that level of monetary accommodation to the economy. In addition, some individual companies had extremely good news, and Abercrombie & Fitch (NYSE: ANF), Triumph Group (NYSE: TGI), and Puma Biotechnology (NASDAQ: PBYI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Shares of Abercrombie & Fitch climbed 6% in the wake of reports that the teen retailer might receive an acquisition bid from a consortium of investors. According to The Wall Street Journal(subscription required), industry peer American Eagle Outfitters (NYSE: AEO) and private equity company Cerberus Capital Management are looking at putting together a potential buyout offer for Abercrombie & Fitch, following speculation that other players in the industry might also be interested in consolidation. A&F has been dealing with takeover speculation for a while, and it has typically noted that any discussions wouldn't necessary translate into actual offers. Yet with Abercrombie set to release its first-quarter financial results Thursday, investors will want to see signs that the company can take care of its challenges on its own -- or else they'll start clamoring more loudly for a buyout to take place.

Image source: Getty Images.

Triumph Group stock soared over 30% after the company announced its fiscal fourth-quarter financial results and resolved a dispute with aircraft manufacturer Bombardier. The aerospace components and systems specialist said that sales fell 13% from year-ago levels, and it posted a GAAP loss of $126.8 million. With challenges in its aerospace structures business, Triumph has focused on amending contracts and addressing operational and financial challenges, and the company's transformation plan has led to improving free cash flow and cost savings. Investors were also happy that Triumph reached a settlement of all of its disputes with Bombardier. Triumph said that the agreement "resets the commercial relationship between [Triumph] and Bombardier and allows each of them to better achieve their business objectives going forward."

Finally, shares of Puma Biotechnology jumped 30%. The biopharmaceutical company earned a hoped-for approval from the U.S. Food and Drug Administration advisory panel looking at its neratinib candidate treatment for breast cancer. The panel voted 12 to 4 in favor of recommending the drug to the FDA, and although panelists expressed some thoughts about potentially limiting the size of the group of women eligible to use the drug, investors nevertheless took the news as a positive. The FDA still needs to make its own decision about Puma's drug, and it isn't bound by the opinion of the advisory panel. Nevertheless, today's recommendation moves Puma one step further to getting a big win under its belt, and shareholders recognized that fact with the second big move in the stock this week.

Offer from The Motley Fool: The 10 best stocks to buy now

Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor, has tripled the S&P 500!*

Tom and David just revealed their ten top stock picks for investors to buy right now.

*Stock Advisor returns as of 5/1/2017.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the original post:
Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today - Madison.com

Posted in Biotechnology | Comments Off on Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today – Madison.com

Puma Biotechnology, Inc. (PBYI) loses confidence of 21 hedge fund managers – Post Analyst

Posted: May 26, 2017 at 8:43 am


pppFocus
Puma Biotechnology, Inc. (PBYI) loses confidence of 21 hedge fund managers
Post Analyst
Puma Biotechnology, Inc. (NASDAQ:PBYI) reached 182.43% versus a 1-year low price of $27.64. The stock was last seen 4.14% higher, reaching at $78.05 on Thursday. At recent session, the prices were hovering between $74.65 and $80. This company ...
Puma Biotechnology (PBYI) At $78.05 Forms Bottom, Ancora Advisors Lifted Its Monsanto Co New (MON) StakeWolcott Daily
Noteworthy Stocks: Puma Biotechnology, Inc.'s (PBYI) closed Thursday at $78.05 with 4.14%, Old Dominion Freight ...Is stories
Will Puma Biotechnology, Inc. (PBYI) Crush EPS Estimates Again ...pppFocus
TRA -Markets Daily -The USA Commerce -Zacks
all 19 news articles »

Continued here:
Puma Biotechnology, Inc. (PBYI) loses confidence of 21 hedge fund managers - Post Analyst

Posted in Biotechnology | Comments Off on Puma Biotechnology, Inc. (PBYI) loses confidence of 21 hedge fund managers – Post Analyst

A new way to slow cancer cell growth – Medical Xpress – Medical Xpress

Posted: May 26, 2017 at 8:42 am

May 25, 2017 All cells go through the "cell cycle," a series of events that culminate in orderly cell growth and division. In cancer, the cell cycle is out of whack; cells divide uncontrollably and invade surrounding tissues. By removing a specific protein from cells, researchers were able to slow the cell cycle. The findings were made in kidney and cervical cancer cells and are a long way from being applied in people. But, the study suggests that targeting this protein could inhibit fast-growing cancer cells and be the basis of a treatment option in the future. Credit: University of Rochester Medical Center

Cancer is an extremely complex disease, but its definition is quite simple: the abnormal and uncontrollable growth of cells. Researchers from the University of Rochester's Center for RNA Biology have identified a new way to potentially slow the fast-growing cells that characterize all types of cancer. The findings, reported today in the journal Science and funded by the National Institutes of Health, were made in kidney and cervical cancer cells in the laboratory and are a long way from being applied in people. But, they could be the basis of a treatment option in the future, the authors said.

Cancer: The Cell Cycle Gone Wrong

All cells go through the "cell cycle," a series of events that culminate in orderly cell growth and division. In cancer, the cell cycle is out of whack; cells divide without stopping and invade surrounding tissues.

Researchers identified a protein called Tudor-SN that is important in the "preparatory" phase of the cell cycle - the period when the cell gets ready to divide. When scientists eliminated this protein from cells, using the gene editing technology CRISPR-Cas9, cells took longer to gear up for division. The loss of Tudor-SN slowed the cell cycle.

"We know that Tudor-SN is more abundant in cancer cells than healthy cells, and our study suggests that targeting this protein could inhibit fast-growing cancer cells," said Reyad A. Elbarbary, Ph.D., lead study author and research assistant professor in the Center for RNA Biology and the department of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry.

Elbarbary, who works in the laboratory of senior study author Lynne E. Maquat, Ph.D., a world-renowned expert in RNA biology, adds that there are existing compounds that block Tudor-SN that could be good candidates for a possible therapy.

Putting the Brakes on Cell Growth

Maquat's team discovered that Tudor-SN influences the cell cycle by controlling microRNAs, molecules that fine tune the expression of thousands of human genes.

When Tudor-SN is removed from human cells, the levels of dozens of microRNAs go up. Boosting the presence of microRNAs puts the brakes on genes that encourage cell growth. With these genes in the "off" position, the cell moves more slowly from the preparatory phase to the cell division phase.

"Because cancer cells have a faulty cell cycle, pursuing factors involved in the cell cycle is a promising avenue for cancer treatment," noted Maquat, director of the Center for RNA Biology and the J. Lowell Orbison Endowed Chair and professor of Biochemistry and Biophysics.

Maquat, who also holds an appointment in the Wilmot Cancer Institute, and Elbarbary have filed a patent application for methods targeting Tudor-SN for the treatment and prevention of cancer. Research next steps include understanding how Tudor-SN works in concert with other molecules and proteins so that scientists can identify the most appropriate drugs to target it.

Keita Miyoshi, Ph.D., staff scientist in Maquat's lab, served as lead study author with Elbarbary. Jason R. Myers and John M. Ashton, Ph.D. from the UR Genomics Research Center played an instrumental role in the study analysis.

Explore further: Blocking cellular quality control mechanism gives cancer chemotherapy a boost

More information: "Tudor-SNmediated endonucleolytic decay of human cell microRNAs promotes G1/S phase transition" Science (2017). science.sciencemag.org/cgi/doi/10.1126/science.aai9372

A University of Rochester team found a way to make chemotherapy more effective, by stopping a cellular quality-control mechanism, according to a study published today in Nature Communications.

Scientists at the University of Dundee have identified a protein that could be key in the fight against cancer.

For the first time, researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival.

Changes to the structure of the protein histone H3.3 may play a key role in silencing genes that regulate cancer cell growth, according to a study led by researchers from the Icahn School of Medicine at Mount Sinai and published ...

A team led by Johns Hopkins researchers has discovered a biochemical signaling process that causes densely packed cancer cells to break away from a tumor and spread the disease elsewhere in the body. In their study, published ...

In a new study, scientists at The University of Texas at Dallas have found that some types of cancers have more of a sweet tooth than others.

Swiss scientists from the University of Geneva (UNIGE), Switzerland, and the University of Basel have created artificial viruses that can target cancer. These designer viruses alert the immune system and cause it to send ...

Earlier this week, for the first time, a drug was FDA-approved for cancer based on disease genetics rather than type.

Cancer is an extremely complex disease, but its definition is quite simple: the abnormal and uncontrollable growth of cells. Researchers from the University of Rochester's Center for RNA Biology have identified a new way ...

All cancer tumors have one thing in common - they must feed themselves to grow and spread, a difficult feat since they are usually in a tumor microenvironment with limited nutrients and oxygen. A study at The University of ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Originally posted here:
A new way to slow cancer cell growth - Medical Xpress - Medical Xpress

Posted in Cell Medicine | Comments Off on A new way to slow cancer cell growth – Medical Xpress – Medical Xpress

Page 1,558«..1020..1,5571,5581,5591,560..1,5701,580..»